search
Back to results

Excitatory Amino Acids and Activated Microglia After Traumatic Brain Injury: a (R)-[11C]PK11195 PET Study

Primary Purpose

Traumatic Brain Injury

Status
Unknown status
Phase
Phase 1
Locations
Netherlands
Study Type
Interventional
Intervention
Positron Emission Tomography
Sponsored by
Amsterdam UMC, location VUmc
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Traumatic Brain Injury focused on measuring Traumatic Brain Injury, PET, microglia

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: 1. Traumatic Brain Injury 2. Age: 18-70 years 3. Haemodynamic and respiratory stable Exclusion Criteria: 1. Penetrating Skull Damage 2. Pregnancy 3. Hb < 6,5 mmol/l unless patient is known to have no history of cardiovascular disease, in which case a Hb < 5,5 mmol/l, will be the exclusion criterion 4. pH < 7,1 at initial arterial blood analysis 5. Previous neurotrauma 6. Current exposure to radiation in the workplace, or history of participation in nuclear medicine procedures, including research protocols 7. Condition which would exclude a clinical MR scan (e.g. pacemaker, shrapnel, metallic prosthesis)

Sites / Locations

  • VU University Medical Centre

Outcomes

Primary Outcome Measures

Glasgow coma scale after 6 months

Secondary Outcome Measures

microglia activation

Full Information

First Posted
September 12, 2005
Last Updated
November 3, 2005
Sponsor
Amsterdam UMC, location VUmc
search

1. Study Identification

Unique Protocol Identification Number
NCT00205582
Brief Title
Excitatory Amino Acids and Activated Microglia After Traumatic Brain Injury: a (R)-[11C]PK11195 PET Study
Official Title
The Role of Excitatory Amino Acids on Neuronal Damage and Outcome After Traumatic Brain Injury: Assessment in Patients Using Microdialysis and (R)-[11C]PK11195 Positron Emission Tomography
Study Type
Interventional

2. Study Status

Record Verification Date
May 2001
Overall Recruitment Status
Unknown status
Study Start Date
May 2001 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2004 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Amsterdam UMC, location VUmc

4. Oversight

5. Study Description

Brief Summary
Excitatory amino acids may be involved in secondary neuronal damage after traumatic brain injury. The amount of microglia activation is an indirect measure of neuronal damage. Micorglia activation will be measured R)-[11C]PK11195 PET 1 week, 1 month and 6 months after brain injury.
Detailed Description
Glutamate and aspartate have been identified as the major excitatory neurotransmitters in the central nervous system. A massive increase in the release of these excitatory amino acids (EEA) has been described following traumatic brain injury. The resulting overstimulation of neuronal EAA receptors, particularly the N-Methyl-D-Aspartate (NMDA) receptors, leads to excessive influx of calcium through receptor gated ion-channels, causing metabolic derangement and finally cell death. Although the exact role of EEA in patients who have suffered severe head injury remains to be established, it has been shown that sustained high intracranial pressure (ICP) and poor outcome are significantly correlated to high levels of EEA using microdialysis. Disadvantages of microdialysis are that it can only be used to evaluate a limited part of the brain and that it can only be applied in the acute phase following injury. The same limits also apply to ICP measurements. Therefore, methods which evaluate both the extent and time course of damage in vivo are urgently needed. Peripheral type benzodiazepine binding sites are a potential candidate for monitoring neuronal damage. They are not normally present in cerebral tissue, but following neuronal damage, the cells involved in the ensuing gliosis show marked expression of these sites. (R)-PK11195 is a ligand that selectively binds to peripheral type benzodiazepine receptors. Labeled with carbon-11 its uptake can be measured with Positron Emission Tomography (PET). Thus, (R)-[11C]PK11195 PET can be used to monitor in-vivo gliosis after brain injury. A maximum of twenty patients with traumatic brain injury will be included in this study. A microdialysis probe will be placed in the brain parenchyma to continuously measure EEA until the first PET scan is performed. Several cerebral and haemodynamic parameters, such as ICP and mean arterial blood pressure, will be registered. All patients will receive two Magnetic Resonance Imaging (MRI) scans to evaluate the extent and anatomical localization of cerebral damage. Three (R)-[11C]PK11195 PET scans will be performed: 1 week, 1 month and 6 months after the injury. Outcome will be determined using several outcome scales, including the Glasgow Outcome Scale at six months. In addition, patients will be investigated by repeated neuropsychological examinations.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Traumatic Brain Injury
Keywords
Traumatic Brain Injury, PET, microglia

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
20 (false)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
Positron Emission Tomography
Primary Outcome Measure Information:
Title
Glasgow coma scale after 6 months
Secondary Outcome Measure Information:
Title
microglia activation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 1. Traumatic Brain Injury 2. Age: 18-70 years 3. Haemodynamic and respiratory stable Exclusion Criteria: 1. Penetrating Skull Damage 2. Pregnancy 3. Hb < 6,5 mmol/l unless patient is known to have no history of cardiovascular disease, in which case a Hb < 5,5 mmol/l, will be the exclusion criterion 4. pH < 7,1 at initial arterial blood analysis 5. Previous neurotrauma 6. Current exposure to radiation in the workplace, or history of participation in nuclear medicine procedures, including research protocols 7. Condition which would exclude a clinical MR scan (e.g. pacemaker, shrapnel, metallic prosthesis)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bart van Berckel, MD; PhD
Organizational Affiliation
Amsterdam UMC, location VUmc
Official's Role
Principal Investigator
Facility Information:
Facility Name
VU University Medical Centre
City
Amsterdam
ZIP/Postal Code
1081 HV
Country
Netherlands

12. IPD Sharing Statement

Learn more about this trial

Excitatory Amino Acids and Activated Microglia After Traumatic Brain Injury: a (R)-[11C]PK11195 PET Study

We'll reach out to this number within 24 hrs